Disorder of visual system
MONDO:0024458A disease that involves the visual system.
Also known as: disease of visual system, disease or disorder of visual system, disorder of visual system, visual system disease, visual system disease or disorder, visual system disorder
3482 clinical trials for this condition and its sub-types, 1 tagged with Disorder of visual system itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of visual system
-
Eye disorder 104 trials · 3,073 incl. sub-types
120 sub-types
- Retinal disorder 89 trials · 961 incl. sub-types Sub-types →
- Corneal disorder 46 trials · 464 incl. sub-types Sub-types →
- Lacrimal apparatus disorder 5 trials · 417 incl. sub-types Sub-types →
- Refractive error 82 trials · 400 incl. sub-types Sub-types →
- Ocular growth disorder 0 trials · 364 incl. sub-types Sub-types →
- Ocular vascular disorder 0 trials · 349 incl. sub-types Sub-types →
- Glaucoma 217 trials · 332 incl. sub-types Sub-types →
- Lens disorder 12 trials · 319 incl. sub-types Sub-types →
- Conjunctival disorder 1 trial · 314 incl. sub-types Sub-types →
- Uveal disorder 1 trial · 234 incl. sub-types Sub-types →
- Eye neoplasm 3 trials · 192 incl. sub-types Sub-types →
- Ocular hypertension 111 trials
- Eye degenerative disorder 0 trials · 97 incl. sub-types Sub-types →
- Autoimmune/inflammatory optic neuropathy 0 trials · 85 incl. sub-types Sub-types →
- Eye accommodation disease 6 trials · 69 incl. sub-types Sub-types →
- Eye infectious disorder 4 trials · 61 incl. sub-types Sub-types →
- Vitreous body disorder 0 trials · 50 incl. sub-types Sub-types →
- Eyelid disorder 4 trials · 47 incl. sub-types Sub-types →
- Gaucher disease 46 trials Sub-types →
- Hereditary optic neuropathy 1 trial · 30 incl. sub-types Sub-types →
- Optic neuritis 21 trials · 25 incl. sub-types Sub-types →
- Asthenopia 24 trials
- Ocular motor apraxia, Cogan type 23 trials
- Anterior segment dysgenesis 2 trials · 21 incl. sub-types Sub-types →
- Choroidal neovascularization 21 trials
- Eye allergy 2 trials · 20 incl. sub-types Sub-types →
- Neurotrophic keratopathy 17 trials
- Mucopolysaccharidosis type 1 11 trials · 16 incl. sub-types Sub-types →
- Alagille syndrome 15 trials Sub-types →
- Netherton syndrome 15 trials
- Ptosis 13 trials · 14 incl. sub-types Sub-types →
- Sandhoff disease 13 trials Sub-types →
- Tay-Sachs disease 13 trials Sub-types →
- GM1 gangliosidosis 12 trials Sub-types →
- Sturge-Weber syndrome 8 trials
- Isolated Pierre-Robin syndrome 8 trials Sub-types →
- Mucopolysaccharidosis type 6 8 trials Sub-types →
- Scotoma 7 trials
- Smith-Lemli-Opitz syndrome 6 trials
- Cerebrotendinous xanthomatosis 6 trials
- Coloboma 4 trials · 6 incl. sub-types Sub-types →
- Exophthalmos 6 trials
- Alpha-mannosidosis 5 trials Sub-types →
- Galactosemia 5 trials Sub-types →
- Niemann-Pick disease type A 4 trials
- Lamellar ichthyosis 4 trials Sub-types →
- Macular telangiectasia 1 trial · 4 incl. sub-types Sub-types →
- Piebaldism 4 trials
- Sjogren-Larsson syndrome 3 trials
- Isolated anophthalmia-microphthalmia syndrome 2 trials · 3 incl. sub-types Sub-types →
- Mucolipidosis type IV 3 trials
- Oculocerebrorenal syndrome 3 trials
- Pigment dispersion syndrome 3 trials
- Scleral disorder 1 trial · 3 incl. sub-types Sub-types →
- Toxic maculopathy due to antimalarial drugs 3 trials
- Galactosialidosis 2 trials
- Nail-patella syndrome 2 trials
- Rhizomelic chondrodysplasia punctata 2 trials Sub-types →
- Vernal keratoconjunctivitis 2 trials
- Visual snow syndrome 2 trials
- Gardner syndrome 1 trial
- Tietz syndrome 1 trial
- X-linked cone dysfunction syndrome with myopia 1 trial
- Acute zonal occult outer retinopathy 1 trial
- Atopic keratoconjunctivitis 1 trial
- Ocular hypotension 1 trial Sub-types →
- 9q33.3q34.11 microdeletion syndrome 0 trials
- Axenfeld anomaly 0 trials
- Cogan syndrome 0 trials
- Ehlers-Danlos syndrome, kyphoscoliotic type 1 0 trials
- Foster-Kennedy syndrome 0 trials
- IRVAN syndrome 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- Ito hypomelanosis 0 trials
- LTBP2-related ocular dysgenesis 0 trials Sub-types →
- Lowry-MacLean syndrome 0 trials
- Marshall syndrome 0 trials
- Peters plus syndrome 0 trials
- Rothmund-Thomson syndrome type 2 0 trials
- SHORT syndrome 0 trials
- Spasmus nutans 0 trials
- Acute annular outer retinopathy 0 trials
- Anterior dislocation of lens 0 trials
- Anterior segment developmental abnormality with extraocular manifestations 0 trials
- Blindness - scoliosis - arachnodactyly syndrome 0 trials
- Chondroectodermal dysplasia with night blindness 0 trials
- Congenital optic disk excavation 0 trials
- Dyssegmental dysplasia-glaucoma syndrome 0 trials
- Ectodermal dysplasia-blindness syndrome 0 trials
- Essential strabismus 0 trials
- Extensive peripapillary myelinated nerve fibers 0 trials
- Familial cavitary optic disk anomaly 0 trials
- Fatty acyl-CoA reductase 1 deficiency 0 trials
- Glaucoma-sleep apnea syndrome 0 trials
- Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome 0 trials
- Hereditary hyperferritinemia with congenital cataracts 0 trials
- Idiopathic linear interstitial keratitis 0 trials
- Isolated angioid streaks 0 trials
- Isolated ankyloblepharon filiforme adnatum 0 trials
- Isolated blepharochalasis 0 trials
- Keratomalacia 0 trials
- Luxation of globe 0 trials
- Megalocornea-intellectual disability syndrome 0 trials
- Mevalonic aciduria 0 trials
- Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome 0 trials
- Microcornea-corectopia-macular hypoplasia syndrome 0 trials
- Microcornea-glaucoma-absent frontal sinuses syndrome 0 trials
- Multiple evanescent white dot syndrome 0 trials
- Neuroocular syndrome 0 trials Sub-types →
- Ocular cystinosis 0 trials
- Ocular dysgenesis caused by defects in PAX6 regulation 0 trials
- Ocular siderosis 0 trials
- Oculodentodigital dysplasia 0 trials Sub-types →
- Ophthalmia nodosa 0 trials
- Phakomatosis pigmentovascularis 0 trials Sub-types →
- Punctate inner choroidopathy 0 trials
- Red color blindness 0 trials
- Stellate multiform amelanotic choroidopathy 0 trials
- Syndromic recessive X-linked ichthyosis 0 trials
- Tyrosinemia type II 0 trials
-
Vision disorder 105 trials · 382 incl. sub-types
7 sub-types
- Visual pathway disorder 1 trial · 201 incl. sub-types Sub-types →
- Blindness (disorder) 38 trials · 80 incl. sub-types Sub-types →
- Amblyopia 38 trials · 39 incl. sub-types Sub-types →
- Color vision disorder 3 trials · 15 incl. sub-types Sub-types →
- Binocular vision disease 4 trials Sub-types →
- Visual agnosia 0 trials · 2 incl. sub-types Sub-types →
- Alice in Wonderland syndrome 0 trials
-
Optic nerve disorder 23 trials · 95 incl. sub-types
8 sub-types
- Optic atrophy 4 trials · 26 incl. sub-types Sub-types →
- Optic neuritis 21 trials · 25 incl. sub-types Sub-types →
- Low tension glaucoma 21 trials
- Anterior ischemic optic neuropathy 8 trials · 10 incl. sub-types Sub-types →
- Optic nerve neoplasm 1 trial · 4 incl. sub-types Sub-types →
- Optic disk drusen 1 trial
- Extensive peripapillary myelinated nerve fibers 0 trials
- Isolated optic nerve aplasia 0 trials
-
Oculomotor nerve paralysis 1 trial · 87 incl. sub-types
5 sub-types
- Supranuclear oculomotor palsy 0 trials · 78 incl. sub-types Sub-types →
- Nuclear oculomotor paralysis 0 trials · 8 incl. sub-types Sub-types →
- Partial third-nerve palsy 0 trials
- Total internal ophthalmoplegia 0 trials
- Total third-nerve palsy 0 trials
-
Kearns-Sayre syndrome 5 trials
-
Myopathy of extraocular muscle 1 trial · 5 incl. sub-types
3 sub-types
- Oculopharyngeal muscular dystrophy 3 trials Sub-types →
- Congenital fibrosis of extraocular muscles 1 trial Sub-types →
- Orbital myositis 0 trials
-
Jaw-winking syndrome 2 trials
2 sub-types
- Marin-Amat syndrome 0 trials
- Inverse Marcus-Gunn phenomenon 0 trials
-
Ocular albinism 1 trial · 2 incl. sub-types
3 sub-types
- Autosomal recessive ocular albinism 0 trials · 1 incl. sub-types Sub-types →
- X-linked recessive ocular albinism 0 trials
- Ocular albinism with late-onset sensorineural deafness 0 trials
-
EEC syndrome 1 trial
-
5 sub-types
- Joubert syndrome 14 0 trials
- Joubert syndrome 16 0 trials
- Joubert syndrome 2 0 trials
- Joubert syndrome 5 0 trials
- Joubert syndrome 9 0 trials
-
RHYNS syndrome 1 trial
-
CHIME syndrome 0 trials
-
Joubert syndrome with ocular defect 0 trials
5 sub-types
- Joubert syndrome 14 0 trials
- Joubert syndrome 15 0 trials
- Joubert syndrome 20 0 trials
- Joubert syndrome 28 0 trials
- Joubert syndrome 3 0 trials
-
Mietens syndrome 0 trials
-
Stern-Lubinsky-Durrie syndrome 0 trials
-
Cataract-glaucoma syndrome 0 trials
Most studied deeper sub-types
-
New Sjögren's drug ASP5502 enters first human tests
Disease control Stopped earlyThis early-stage study tested a new oral drug, ASP5502, for primary Sjögren's syndrome, an autoimmune condition causing dry eyes and mouth. It involved 116 healthy adults and patients to check safety and how the body processes the drug. The study was terminated, but results may g…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Tiny doses of avastin tested against laser for preemie eye disease
Disease control Stopped earlyThis study tested a low dose of the drug bevacizumab (Avastin) against standard laser treatment for retinopathy of prematurity, an eye disease that can blind premature infants. Sixteen babies with severe disease were enrolled. The goal was to see if the drug could control the dis…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Radioactive drug targets Hard-to-Treat melanoma in early trial
Disease control Stopped earlyThis early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, an…
Phase 1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can light therapy dry out a swollen retina?
Disease control Stopped earlyThis pilot study tests whether shining near-infrared light on the eye can reduce macular edema—swelling in the central retina—caused by a retinal vein occlusion. Six participants with this condition will receive 12 light treatments over about five weeks. The main goal is to see i…
Sponsor: University of Sydney • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental antibody takes aim at eye inflammation
Disease control Stopped earlyThis study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is …
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a drug duo tame a rare eye cancer that has spread?
Disease control Stopped earlyThis trial is testing whether combining two drugs—pembrolizumab and lenvatinib—can help people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. Participants receive both drugs for up to two years. The study measures how long people liv…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cataract lens shows promise in early trial
Disease control Stopped earlyThis study tested a new type of artificial lens (TECNIS DEN00V) for people having cataract surgery. It compared the new lens to a standard lens in 243 adults with cataracts. The goal was to see if the new lens improves vision at arm's length (66 cm) while keeping good distance vi…
Sponsor: Johnson & Johnson Surgical Vision, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New eye injection targets Blindness-Causing lesions
Disease control Stopped earlyThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can an ancient herbal remedy ease swelling in the eye?
Disease control Stopped earlyThis phase 2 trial tests whether a modified Chinese herbal formula, Shenling Baizhu San, can reduce swelling in the retina (macular edema) and improve vision. Adults diagnosed with macular edema take either the herbal granules or a placebo twice daily for 12 weeks. The study meas…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Experimental drug BVD-523 tested for rare eye cancer, but trial stopped early
Disease control Stopped earlyThis study tested a drug called BVD-523 (Ulixertinib) in 13 people with advanced uveal melanoma, a rare eye cancer that has spread. The drug works by blocking certain proteins that help cancer grow. The trial was terminated early, so results are limited and it's unclear how well …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can special lenses put the brakes on childhood myopia?
Disease control Stopped earlyThis trial tests whether a new type of spectacle lens can slow the progression of myopia (nearsightedness) in children aged 8 to 13. Over 12 months, researchers measure changes in eye length and prescription, comparing results to a historical group that wore standard lenses. The …
Sponsor: Essilor International • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Violet light lamp tested to stop Kids' eyesight from getting worse
Disease control Stopped earlyThis study tests whether using a violet light lamp at home can slow the progression of myopia (nearsightedness) in children. 72 kids aged 5 to 12 will use either a violet light lamp or a regular white light lamp for 12 months. Researchers will measure changes in eye length and vi…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New proton therapy aims to save eyes from removal in large melanoma cases
Disease control Stopped earlyThis study tested two different proton therapy schedules for people with large choroidal melanomas (eye cancer) that would normally require removal of the eye. The goal was to see if a gentler radiation schedule could control the tumor and avoid severe side effects, allowing pati…
Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Glaucoma supplement trial fizzles: MEMOPTIC study halted early
Disease control Stopped earlyThis study tested whether a daily tablet called MEMOPTIC (containing citicoline, magnesium, and Ginkgo biloba) could help preserve vision in people with open-angle glaucoma when added to their usual eye-pressure-lowering treatments. The trial planned to follow 15 patients for two…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New eye lens aims to sharpen Mid-Range sight after cataracts
Disease control Stopped earlyThis study tested a new type of artificial lens (enVista Aspire) for people having cataract surgery. The goal was to see if it improves intermediate vision, like seeing a computer screen, better than standard lenses. The trial was stopped early and included 27 adults aged 22 and …
Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Herbal supplement fails to show clear benefit in optic neuritis pilot
Disease control Stopped earlyThis small pilot study tested whether adding gypenosides (a herbal supplement) to standard steroid treatment could help protect the nerve at the back of the eye in adults having their first episode of acute optic neuritis. Ten participants were enrolled, but the study was stopped…
Phase 2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Eye stroke treatment put to the test: can clot busters save sight?
Disease control Stopped earlyThis study tested whether giving a clot-busting drug (tenecteplase or alteplase) within 4.5 hours of an eye stroke could restore vision. Eye stroke, or central retinal artery occlusion, is a blockage in the eye's main artery that often causes permanent vision loss. The trial aime…
Phase 3 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cataract device tested, but study halted early
Disease control Stopped earlyThis study compared a new device called miCOR, which uses low energy to break up cataracts, to standard cataract surgery. About 402 adults with cataracts were planned to take part. The study was terminated early, so we don't have full results on whether the new device is better o…
Sponsor: Carl Zeiss Meditec, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug for rare skin disease fails to reach goal
Disease control Stopped earlyThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Eye injection study for diabetes-related vision loss ends early
Disease control Stopped earlyThis study tested a single injection of avoralstat into the eye for people with diabetic macular edema, a condition that causes vision loss in diabetes. Only 3 adults took part before the study was stopped early. The main goal was to check safety and see if the drug might help re…
Phase 1 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Eye drop combo study for glaucoma halted early
Disease control Stopped earlyThis study tested two different combinations of eye drops to lower eye pressure in people with open-angle glaucoma or ocular hypertension. The goal was to see which combination worked better over 90 days. The study was stopped early and included 28 participants.
Phase 4 • Sponsor: Laboratorios Sophia S.A de C.V. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Sjögren's drug trial halted: what happened?
Disease control Stopped earlyThis study tested an experimental drug called HZN-1116 in 209 people with Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The goal was to see if the drug could reduce disease activity and symptoms. The trial was terminated early, so results may not be availa…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Artificial cornea implant aims to restore sight in the blind
Disease control Stopped earlyThis trial tested a device called the CorNeat KPro, an artificial cornea, in 15 legally blind adults who could not get a standard cornea transplant. The goal was to see if the implant is safe and can improve vision. The study was terminated early, so full results are not availabl…
Sponsor: CorNeat Vision Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental pill for rare nerve disease shows early promise in tiny trial
Disease control Stopped earlyThis early-phase trial tested the drug zanubrutinib in just 6 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the nerves. Participants took the pill twice daily for a year to see if it could prevent relapses. However, t…
Phase 2 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising drug trial for thyroid eye disease halted early
Disease control Stopped earlyThis study tested a drug called secukinumab in adults with active, moderate to severe thyroid eye disease, a condition that causes bulging eyes and discomfort. The trial aimed to see if the drug could reduce eye bulging and inflammation. However, the study was stopped early and o…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug aims to stop relapses in rare brain disease
Disease control Stopped earlyThis study tested an experimental drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal was to see if RC18 could prevent relapses and slow disability. Participants had to …
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Video game therapy for lazy eye shows early promise, but trial cut short
Disease control Stopped earlyThis trial tested a computer-based therapy called AmblyoFix for treating lazy eye (amblyopia) in 40 people aged 8 to 19. Participants either used the therapy for 90 minutes daily or wore a standard eye patch. The study was stopped early, and only 4-week data is available, making …
Sponsor: Eyesight Electronics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental DME pill trial ends early after just one patient
Disease control Stopped earlyThis early-stage study tested a new oral drug called K9 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The trial was stopped early and only enrolled one person. The main goal was to check safety and measure changes in retinal swelling and…
Phase 1 • Sponsor: Michelle Abou-Jaoude • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Glaucoma device Follow-Up study ends early
Disease control Stopped earlyThis study looked at the long-term safety and effectiveness of the STREAMLINE® Surgical System in people with open-angle glaucoma. It included 17 patients who had already taken part in an earlier trial of the same device. The goal was to see if the device continued to safely lowe…
Sponsor: New World Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Epilepsy drug study halted early: BHV-7000 shows limited promise
Disease control Stopped earlyThis study tested whether BHV-7000, taken alongside other medications, could reduce generalized tonic-clonic seizures in people with idiopathic generalized epilepsy. The trial was terminated early and enrolled only 27 adults aged 18-75. The main goal was to see how long it took f…
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Laser-Like eye surgery device falls short – trial stopped early
Disease control Stopped earlyThis study tested a device called the ELITA System to reduce or eliminate nearsightedness (myopia) and astigmatism. It involved 96 adults aged 22 and older who received a lenticule removal procedure in one or both eyes. The trial was terminated early, so the planned results on sa…
Sponsor: Johnson & Johnson Surgical Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control Stopped earlyThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Phase 2/3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer drug imatinib tested for rare eye melanoma – but trial stops early
Disease control Stopped earlyThis phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclea…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Eye infection breakthrough: new trial tests antivirals to save sight
Disease control Stopped earlyThis study compared two antiviral medicines (oral valganciclovir and topical ganciclovir 2%) against a placebo for treating CMV-related inflammation in the front of the eye. The goal was to see which approach better controls the infection and reduces complications like pain, glau…
Phase 2/3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control Stopped earlyThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control Stopped earlyThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered virus takes on Hard-to-Treat melanoma
Disease control Stopped earlyThis early-stage trial tested a modified virus (VSV-IFNbetaTYRP1) in 12 patients with advanced melanoma that had spread or could not be removed by surgery. The virus was designed to infect and kill melanoma cells while also boosting the immune system's attack. The main goals were…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Eye drug trial for rare macular disease stops early – only 16 patients enrolled
Disease control Stopped earlyThis phase 3 trial tested aflibercept (Eylea) eye injections against placebo in 16 people with macular telangiectasia type 1, a rare condition that causes vision loss. The study aimed to see if aflibercept could reduce swelling in the macula. However, the trial was terminated ear…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Light therapy for stubborn eyelid lumps? tiny trial ends early
Disease control Stopped earlyThis study tested whether intense pulsed light (IPL) can help treat chalazion, a common eyelid lump. Only 4 adults with a fresh chalazion were enrolled, and the trial was stopped early. Because of the very small size, we cannot say if IPL works or is safe for this condition.
Sponsor: Lumenis Be Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control Stopped earlyThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase 1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New eye ointment aimed at soothing chronic eyelid inflammation
Disease control Stopped earlyThis study tested a medicated ointment called pimecrolimus 0.3% for people with blepharitis, a condition that causes red, irritated eyelids. The trial planned to include 477 participants aged 2 and older, applying the ointment twice daily to the eyelid margins. The main goal was …
Phase 3 • Sponsor: Famy Life Sciences, a Viatris Company • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Glaucoma supplement trial halted early – no clear results
Disease control Stopped earlyThis study tested whether a daily dietary supplement called GlaucoCetin could improve vision in people with open-angle glaucoma who already had some vision loss. Only 12 participants were enrolled before the trial was terminated early. The supplement contained a mix of ingredient…
Sponsor: Wills Eye • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental gene therapy aims to halt vision loss in rare blindness
Disease control Stopped earlyThis study tested a gene therapy for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment involved injecting a corrected gene under the retina in one eye. The trial included 19 people aged 13 and older with a specific genetic defect. The m…
Phase 1/2 • Sponsor: eyeDNA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental cancer drug KZR-261 tested in early trial
Disease control Stopped earlyThis early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…
Phase 1 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
VR headsets tested as a possible treatment for blindness
Disease control Stopped earlyThis study tested whether using a virtual reality headset for one-hour sessions could help regenerate damaged optic nerves and improve vision in people with glaucoma or other retinal diseases. The idea came from promising results in rodents. However, the trial was terminated earl…
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Eye injections tested to save sight in rare coats disease
Disease control Stopped earlyThis study tested whether anti-VEGF injections into the eye could help treat Coats disease, a rare condition that causes abnormal blood vessels and fluid buildup in the retina, potentially leading to blindness. The trial included 18 people with early-stage Coats disease who had n…
Phase 3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Seizure drug study ends early – safety results awaited
Disease control Stopped earlyThis study looked at the long-term safety of an experimental drug called CVL-865 in adults whose focal seizures were not controlled by other medications. About 105 people who completed a previous trial took CVL-865 alongside their usual seizure drugs for up to 57 weeks. The study…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could vitamin B2 and sunlight replace costly eye surgery?
Disease control Stopped earlyThis study tested whether taking vitamin B2 (riboflavin) and getting natural sunlight could strengthen the cornea in people with keratoconus, a condition that causes the cornea to thin and bulge. The approach aimed to be a simpler, cheaper alternative to the standard cross-linkin…
Sponsor: University of Missouri-Columbia • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Laser surgery offers new hope for kids with stubborn lazy eye
Disease control Stopped earlyThis study looked at whether laser eye surgery (PRK) could improve vision in children aged 2 to 17 with lazy eye (amblyopia) caused by large differences in prescription between eyes or very high nearsightedness, farsightedness, or astigmatism. These children had not improved afte…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New surgical trick may fix stubborn eye holes
Disease control Stopped earlyThis study tested a new surgical technique for macular holes that remained open after standard treatment. The procedure involves moving a thin membrane from the eye to cover the hole. Only 16 people were enrolled, and the study was stopped early, so we don't yet know if this appr…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Glaucoma pressure fight: new device vs laser – which wins?
Disease control Stopped earlyThis study tested a new device (VISCO™360) against a standard laser treatment to lower eye pressure in adults with open-angle glaucoma. Only 29 people took part before the study was stopped early. The goal was to see which method works better and is safer for controlling the dise…
Sponsor: Sight Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising drug for recurrent brain tumor in kids falls short in early trial
Disease control Stopped earlyThis study tested an oral drug called CX-4945 (silmitasertib) in 21 children with recurrent SHH medulloblastoma, a rare brain tumor. The trial aimed to find the best dose and see if the drug could shrink tumors. However, the study was stopped early, so we don't have clear answers…
Phase 1/2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Glaucoma device showdown ends early: only 10 patients enrolled
Disease control Stopped earlyThis study aimed to compare two surgical devices—the OMNI system and the iStent inject—for lowering eye pressure in people with open-angle glaucoma who already had cataract surgery. The trial was terminated early and only enrolled 10 participants, so results are limited. Both dev…
Sponsor: Sight Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Liver-Directed drug combo shows promise for rare eye cancer
Disease control Stopped earlyThis study tested a new drug called SD-101, given directly into the liver through a special pressure-enabled infusion, alone or with standard immunotherapy drugs. It was for adults with a rare eye cancer (uveal melanoma) that had spread mainly to the liver. The main goals were to…
Phase 1 • Sponsor: TriSalus Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Glaucoma Drug-Eluting contact lens trial halted after single patient
Disease control Stopped earlyThis study tested a special contact lens that slowly releases the glaucoma drug latanoprost, aiming to replace daily eye drops. Only one person enrolled before the study was stopped early. The goal was to check safety and whether the lens could lower eye pressure, but no conclusi…
Phase 1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Seizure drug study halted after just one patient
Disease control Stopped earlyThis study tested the drug perampanel in adults whose seizures did not stop with standard treatments. The goal was to see if it could safely stop seizures and reduce time in the hospital. Only one person enrolled before the study was ended early, so no clear conclusions can be dr…
Phase 4 • Sponsor: Wayne State University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Dravet syndrome drug trial halted early: did lorcaserin help?
Disease control Stopped earlyThis study tested whether lorcaserin, when added to current medications, could reduce convulsive seizures in people with Dravet syndrome, a severe form of epilepsy. The trial planned to enroll about 22 participants aged 2 and older, but it was terminated early. The main goal was …
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Glaucoma implant trial halted early – what we know
Disease control Stopped earlyThis study tested a new medical device called Supraflow v1.3, which is implanted in the eye to help drain fluid and lower pressure in people with open-angle glaucoma. The trial included 22 patients whose eye pressure was not controlled with medication. However, the study was term…
Sponsor: Ciliatech • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising combo for eye cancer stalls after only 3 patients enrolled
Disease control Stopped earlyThis phase II trial tested a combination of precise radiation therapy followed by injections of aflibercept (Eylea) in people with uveal melanoma, a rare eye cancer. The goal was to see if this approach could control the tumor while reducing side effects like swelling or damage t…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control Stopped earlyThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase 3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Eye drug trial halted: could danicopan still slow blind spots?
Disease control Stopped earlyThis Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:21 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control Stopped earlyThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase 1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
Can your phone spot eye cancer? app tested for retinoblastoma
Diagnosis Stopped earlyThis study tested a smartphone app called CRADLE that uses a photo to detect leukocoria (a white glow in the pupil), which can be a sign of retinoblastoma, cataracts, or glaucoma. Researchers planned to compare the app's accuracy to a standard eye exam in children with these cond…
Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Portable devices could take the guesswork out of eye pressure checks
Diagnosis Stopped earlyEye pressure is usually measured with a technique called Goldmann applanation tonometry, which doctors consider the gold standard but which depends on the examiner's skill and offers limited repeatability. Researchers at Duke University are testing automated versions of this meas…
Sponsor: Duke University • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can a new scale give voice to pain in the blind?
Diagnosis Stopped earlyThis study tests whether a new tool, the VISIODOL® scale, can help people with visual impairment communicate pain. Researchers will compare pain ratings from this scale with those from a standard numerical scale during heat-induced pain. The study includes healthy volunteers with…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
AI reads eye photos to spot Diabetes-Related vision loss
Diagnosis Stopped earlyThis study tests whether an artificial intelligence program called NeoRetina can accurately detect diabetic retinopathy and diabetic macular edema from simple eye photographs. Researchers will compare the AI's analysis to standard exams by eye doctors. The goal is to see if this …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Virtual reality could spot eye nerve damage earlier than flashlight test
Diagnosis Stopped earlyThis study tested whether a virtual reality headset combined with machine learning can measure pupil reactions more reliably than the standard flashlight test for Relative Afferent Pupillary Defect (RAPD). About 71 adults with and without known RAPD took part. Researchers compare…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New eye scanner software could sharpen diagnosis of macular degeneration
Diagnosis Stopped earlyThis study tested a new software called AngioScan, used with an already-approved eye camera, to see if it can take better pictures of the back of the eye. Researchers looked at 150 patients with retinal problems like macular degeneration. The goal was to find out if the software …
Sponsor: University of California, Los Angeles • Aim: Diagnosis
Last updated Jun 27, 2026 12:10 UTC
-
Corn could be key to saving your eyesight
Prevention Stopped earlyThis study looked at whether eating corn rich in zeaxanthin (a natural pigment) could increase the density of the macular pigment in the eye, which may help prevent age-related macular degeneration (AMD), a leading cause of blindness. Nine healthy volunteers aged 20-35 ate a dail…
Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
New antibody shots aim to stop itchy eyes from birch pollen
Symptom relief Stopped earlyThis study tests two experimental drugs (REGN5713 and REGN5715) given alone or together to reduce eye allergy symptoms caused by birch pollen. About 350 adults with birch pollen allergy will receive the drugs or a placebo and then be exposed to pollen in a controlled setting. The…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can a Once-Daily eye drop ease pain and swelling after cataract surgery?
Symptom relief Stopped earlyThis trial tests whether OCS-01, a dexamethasone eye drop, can reduce inflammation and pain after cataract surgery. About 117 adults scheduled for cataract removal will receive either the active drop or a placebo once daily. The study measures how well the drop clears eye inflamm…
Phase 3 • Sponsor: Oculis • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New eye drops aim to soothe dry eye inflammation
Symptom relief Stopped earlyThis study tested whether Thealoz Total eye drops can reduce inflammation and improve symptoms in people with chronic dry eye disease. The drops contain hyaluronic acid for lubrication, plus trehalose and NAAGA to fight inflammation. The trial planned to enroll 30 adults with mod…
Phase 4 • Sponsor: Medical University of Vienna • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Dry eye drops duel: which one works better?
Symptom relief Stopped earlyThis study compared two different eye drops (Systane PRO and Refresh Optive Mega-3) to see which one works better for people with dry eye. Twenty adults with moderate dry eye symptoms were enrolled, but the study was stopped early. Participants filled out questionnaires about the…
Phase 4 • Sponsor: Scripps Poway Eyecare and Optometry • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Tiny drops, big hope? study tests nanodropper for glaucoma
Symptom relief Stopped earlyThis study tested whether a device called Nanodropper, which makes smaller eye drops, works as well as standard eye drops for lowering eye pressure in people with glaucoma or ocular hypertension. The study enrolled 16 adults who already used a common glaucoma drop. The goal was t…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New stent aims to dry up tears after eye surgery
Symptom relief Stopped earlyThis study tested a redesigned lacrimal stent, called the Slit Stent II, for people with severe tearing (epiphora) caused by a blocked tear duct. The stent has slits to allow tears to drain while it is still in place after DCR surgery. The trial planned to enroll 5 people to chec…
Sponsor: Thomas Gardner • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New gel aims to soothe dry eyes in glaucoma patients
Symptom relief Stopped earlyThis study looked at whether a preservative-free eye gel called IRIDIUM® could help relieve dry eye symptoms in people with glaucoma or high eye pressure who were already using multiple eye drop medications. The goal was to see if the gel improved comfort and quality of life. The…
Sponsor: Fidia Farmaceutici s.p.a. • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Cooling the brain through the nose: new device tested for ICU fever
Symptom relief Stopped earlyThis study tested a device called CoolStat that is placed in the nose to cool down brain-injured patients with fever in the ICU. The goal was to see if it could safely and quickly bring their temperature to normal. Only 9 patients were enrolled before the study was stopped early,…
Sponsor: CoolTech LLC • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Glasses give kids a brighter future: study tests impact on learning and mental health
Symptom relief Stopped earlyThis study gave free eyeglasses to over 1,800 students aged 9-20 in Sierra Leone who had trouble seeing. Researchers wanted to find out if wearing glasses would improve their math and reading skills, and also help with anxiety and social well-being. The study was planned to last …
Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
CBD study for baby seizures halted early
Symptom relief Stopped earlyThis study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was termina…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Warm compress showdown: can a new device beat the old way for dry eye?
Symptom relief Stopped earlyThis study compared the TearCare system, a device that applies heat to the eyelids, to standard warm compresses and lid massage for people with dry eye disease. The goal was to see if TearCare is safe and better at improving tear stability and reducing eye discomfort. The study p…
Sponsor: Sight Sciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New eye drop shows promise for Sjögren's dry eye relief
Symptom relief Stopped earlyThis early-phase trial tested a new eye drop called rhPRG4 in 8 people with Sjögren's syndrome-related dry eye. Participants received either the active drop or a placebo, then switched after 90 minutes. The study measured eye dryness and safety over a single day. Because the tria…
Phase 1/2 • Sponsor: Lubris Bio Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Eye tests may predict dry eye relief from artificial tears
Symptom relief Stopped earlyThis study aimed to see if certain eye tests could predict which people with dry eye disease would get relief from over-the-counter artificial tears. Researchers planned to enroll 66 adults with dry eye, but the study was terminated early with only 36 participants. Participants u…
Phase 4 • Sponsor: Tufts Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Contact lens coating replenisher tested for rare eye conditions
Symptom relief Stopped earlyThis study tested a monthly solution called Tangible Boost that is meant to restore a special coating on contact lenses. The goal was to see if it could improve comfort and vision in people with severe dry eye from Stevens-Johnson syndrome, Sjogren's syndrome, or graft-versus-hos…
Sponsor: Tangible Science • Aim: Symptom relief
Last updated Jun 26, 2026 18:06 UTC
-
Home infusions may help patients stick to treatment
Knowledge-focused Stopped earlyThis study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to continue their IV treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico. No new treatments are given; the goal is to un…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can genetics predict the worsening of geographic atrophy?
Knowledge-focused Stopped earlyThis study follows people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots, to see how their vision changes over time. Researchers will measure visual function, such as reading speed and sensitivity to light, and track the growth …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Gene Editing's lasting impact: a 10-Year safety watch
Knowledge-focused Stopped earlyThis study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists dive into rare cholesterol disorders to uncover clues
Knowledge-focused Stopped earlyThis study looks at rare genetic disorders where the body can't make cholesterol properly, which can cause birth defects and learning problems. Researchers collect blood, urine, and tissue samples from affected people and their families to learn more about these conditions. The g…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Russian NMOSD patients under the microscope: no new drug, just Real-World data
Knowledge-focused Stopped earlyThis study is not testing a new treatment. Instead, it observes how 100 adults with a rare autoimmune disease called NMOSD are managed in everyday Russian clinics. Researchers will collect medical records and follow patients over time to understand their symptoms, treatments, and…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused Stopped earlyThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Tiny study on eye pressure fluctuation in glaucoma patients ends early
Knowledge-focused Stopped earlyThis study aimed to measure how eye volume changes (a sign of pressure fluctuation) before and after cataract surgery in patients with exfoliative glaucoma, a type of glaucoma common in Brittany. Only 6 adults were enrolled before the study was terminated. The goal was to see if …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Tiny genetic clues may unlock eye disease mysteries
Knowledge-focused Stopped earlyThis study looked at people with cone disorders, a type of inherited eye disease that affects color vision and sharp sight. Researchers analyzed genetic changes of unknown significance to see if they cause disease. The goal was to improve genetic diagnosis, not to test a treatmen…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Glaucoma patients test vision from home in new study
Knowledge-focused Stopped earlyThis study looked at whether people with glaucoma would keep doing vision tests at home on an iPad every two weeks for six months. Eight patients took part. The goal was to see how often they tested and if the home test could catch worsening vision. Researchers also asked patient…
Sponsor: Andrew Pouw, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New EyeCheck device put to the test for glaucoma monitoring
Knowledge-focused Stopped earlyThis study aimed to see if a new device called the EyeCheck monitor can measure eye pressure as accurately as standard tools in people with glaucoma or suspected glaucoma. Twenty-two participants used the device during a clinic visit. The study was stopped early, so results are l…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Eye test may forecast kidney failure after cancer surgery
Knowledge-focused Stopped earlyThis study looked at whether special eye scans (OCT-angiography) can predict how well the remaining kidney will work one year after kidney removal for cancer. Researchers enrolled 30 adults scheduled for total nephrectomy. The goal was to see if retinal blood vessel patterns coul…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Timing of heart scans after arrest: does it matter?
Knowledge-focused Stopped earlyThis study looked at 212 patients who woke up after a cardiac arrest outside the hospital. Researchers compared getting a heart angiogram right away versus waiting 12-24 hours. The goal was to see if immediate imaging reduces the risk of death, shock, or another cardiac arrest. T…
Sponsor: Aarhus University Hospital Skejby • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Peeling eye membrane during retinal surgery: help or hype?
Knowledge-focused Stopped earlyThis study looked at whether peeling a thin membrane inside the eye (the internal limiting membrane) during surgery for a detached retina helps patients see better and prevents scar tissue. The trial was stopped early after enrolling only 21 people, so the results are not strong …
Sponsor: Vienna Institute for Research in Ocular Surgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New eye camera could spot hidden signs of blindness
Knowledge-focused Stopped earlyThis study tested a new, non-invasive eye imaging method called hyperspectral imaging. It takes pictures of the back of the eye using many different colors of light to find details not visible with standard cameras. About 679 adults with healthy eyes or eye diseases like diabetic…
Sponsor: Center for Eye Research Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Blood protein may predict seizure return, study halted early
Knowledge-focused Stopped earlyThis study looked at whether measuring a protein called S100B in the blood right after a first seizure could help predict if someone will have more seizures within a year. The researchers planned to follow 37 adults for one year, but the study was stopped early. The goal was to f…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New score could help eye surgeons predict who sees best after surgery
Knowledge-focused Stopped earlyThis study aimed to validate a scoring system that predicts whether patients will have good vision one year after combined cataract and epiretinal membrane surgery. The score uses factors like age, symptom duration, and initial vision. Researchers planned to enroll 164 adults age…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Rare disease study aims to map MLIV's natural course
Knowledge-focused Stopped earlyThis study followed 7 people with Mucolipidosis Type IV (MLIV) to learn how the disease naturally progresses. Researchers used tests like neuropsychological exams, blood and urine tests, and brain MRIs to find better ways to measure the disease. The goal was to improve future cli…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Scientists dig into DNA to unravel rare eye disorders
Knowledge-focused Stopped earlyThis study looked at over 100 people with inherited retinal dystrophies, a group of rare eye diseases that can cause vision loss. Researchers collected genetic and eye exam data to find links between specific gene mutations and symptoms. The goal was to better understand these di…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Laser vs. alcohol: which eye surgery method causes less haze?
Knowledge-focused Stopped earlyThis study compared two methods of removing the clear outer layer of the eye (the epithelium) during laser vision correction for nearsightedness and astigmatism. One method uses a laser, the other uses alcohol and manual scraping. The goal was to see which approach leads to less …
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Sjögren's dry eye study probes corneal nerve damage
Knowledge-focused Stopped earlyThis study aimed to find out how many people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. The study w…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Tiny study probes how seizure meds affect brain wiring after injury
Knowledge-focused Stopped earlyThis pilot study aimed to see if antiseizure drugs like phenobarbital and levetiracetam change brain connectivity patterns in people with severe acute brain injury and reduced consciousness. Only 5 participants were enrolled before the study was terminated. Researchers used resti…
Phase 4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Glaucoma screening study halted after only 26 participants
Knowledge-focused Stopped earlyThis study aimed to collect eye scan data from people with and without glaucoma to develop a new screening tool called the Topcon Health Score. The researchers planned to use a special camera to measure the thickness of nerve layers in the eye. However, the study was terminated e…
Sponsor: Topcon Corporation • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:52 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused Stopped earlyThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC